Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,850 result(s) found for: Breast cancer. Displaying page 5 of 93.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-002406-32 Sponsor Protocol Number: 2018-0601 Start Date*: 2018-11-19
    Sponsor Name:Institut de Cancérologie Lucien Neuwirth
    Full Title: HOMEORAD : Randomized Phase III Trial Evaluating Homeopathic Radium Bromatum® Impact on the Prevention and Treatment of Radiodermites in Breast Cancer Patients
    Medical condition: Indication of curative radiotherapy after conservative breast cancer surgery. Accepted scheme of radiotherapy: 50 Gy (main) + 16 Gy on the tumoral bed (supplement of dose).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002814-37 Sponsor Protocol Number: 1200.5 Start Date*: 2006-12-07
    Sponsor Name:Boehringer Ingelheim France S.A.S.
    Full Title: A phase II study of BIBW 2992 added to letrozole in patients with estrogen receptor positive hormone refractory metastatic breast cancer progressing on letrozole
    Medical condition: Estrogen receptor positive, hormone refractory, metastatic breast adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000967-24 Sponsor Protocol Number: HED-324-PAE-0090-I Start Date*: 2005-12-30
    Sponsor Name:Technical University of Munich
    Full Title: Evaluation of Response Rate to Pre-operative Docetaxel + Herceptin study part A and Docetaxel study part B In Locally Advanced Breast Cancer Patients, Stratified by HER2-Status, Trial Phase II
    Medical condition: therapeutic principles of primary systemic (=neo adjuvant) chemotherapy. In addition to the increased number of breast conserving operations, that could be already achieved by partially remission,...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012623-28 Sponsor Protocol Number: SNDX-275-0301 Start Date*: 2009-08-17
    Sponsor Name:Syndax Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer,...
    Medical condition: ER+ Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012439-14 Sponsor Protocol Number: 155-CL-036 Start Date*: 2010-01-26
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer
    Medical condition: Adenocarcinoma of the breast that is HER2 negative.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) BE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003929-83 Sponsor Protocol Number: ML 20469/GOIRC Start Date*: 2006-11-23
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
    Medical condition: Patients with advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003064-19 Sponsor Protocol Number: NeoTEC Start Date*: 2008-12-30
    Sponsor Name:Universität Leipzig
    Full Title: Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma
    Medical condition: Primary mamma carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000075-13 Sponsor Protocol Number: GBG65 Start Date*: 2011-06-20
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter non-randomized phase II study to evaluate nab-paclitaxel in metastatic breast cancer patients failing a solvent based taxane as (neo-)adjuvant treatment
    Medical condition: Evaluate nab-paclitaxel in metastatic breast cancer patients failing a solvent based taxane as (neo-)adjuvant treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003752-38 Sponsor Protocol Number: om 169 Start Date*: 2003-12-09
    Sponsor Name:OSPEDALE ONCOLOGICO DI BARI
    Full Title: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer
    Medical condition: advancer breast carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003596-12 Sponsor Protocol Number: C/21/07 Start Date*: 2008-01-28
    Sponsor Name:Imperial College of Science Technology and Medicine
    Full Title: A neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer
    Medical condition: This trial will involve postmenopausal patients with histologically confirmed breast tumours in whom it is felt cytoreductive systemic therapy would enable conservative surgery to be carried out.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2011-005230-18 Sponsor Protocol Number: MA.32 Start Date*: 2012-07-03
    Sponsor Name:NCIC Clinical Trials Group
    Full Title: A Phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer.
    Medical condition: Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000599-24 Sponsor Protocol Number: iOM-02282 Start Date*: 2014-12-18
    Sponsor Name:Universitätsklinikum Essen, Westdeutsches Tumorzentrum
    Full Title: Molecularly stratified parallel group phase II trial of the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative...
    Medical condition: The study population includes patients with histologically, progressive, inoperable (locally advanced or metastatic) hormone receptor (HR)–positive, HER2-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020395-28 Sponsor Protocol Number: ARD11588(MM-121-02-02-03) Start Date*: 2011-04-14
    Sponsor Name:MERRIMACK PHARMACEUTICALS
    Full Title: Estudio de fase II, aleatorizado, doble ciego de exemestano +/- MM-121 en mujeres posmenopáusicas con cáncer de mama Her2 negativo localmente avanzado o metastásico, con receptores de estrógeno pos...
    Medical condition: cáncer de mama_____Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002889-41 Sponsor Protocol Number: UC-BCG-2103 Start Date*: 2022-04-29
    Sponsor Name:UNICANCER
    Full Title: LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in women with HR+ HER2- breast cancer at very low risk of metastasis
    Medical condition: Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083237 Luminal A breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-006031-30 Sponsor Protocol Number: GIM8 OVER Start Date*: 2007-12-20
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A Randomized Trial with factorial Design comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in metastatic breast cancer progressing after Aromatase Inhibitor therapy
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001856-36 Sponsor Protocol Number: RF-2016-02362383 Start Date*: 2018-08-07
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE THE ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER EBC ATRA TRIAL
    Medical condition: Patients with newly, untreated, resectable HR+/HER2- eBCs, suitable for pre-operative therapy with anastrozole
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001054-34 Sponsor Protocol Number: D0816C00018 Start Date*: 2018-01-11
    Sponsor Name:AstraZeneca AB
    Full Title: LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) FR (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013432-20 Sponsor Protocol Number: ISI2009-02 Start Date*: 2009-08-04
    Sponsor Name:Charité Campus Mitte
    Full Title: Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging
    Medical condition: Breast tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020772-38 Sponsor Protocol Number: IRST 174.05 Start Date*: 2010-09-13
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Br...
    Medical condition: Patients with primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004144-23 Sponsor Protocol Number: 26866138-BCA-2001 Start Date*: 2007-02-12
    Sponsor Name:AZ St Augustinus, Wilrijk
    Full Title: Clinical Trial Application for a Phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance.
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 13:25:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA